The donor-dependent supply of platelets is frequently insufficient to meet transfusion needs.
To address this issue, we developed a clinically applicable strategy for the derivation of …

Human induced pluripotent stem cells (iPSCs) provide a potentially replenishable source for
the production of transfusable platelets. Here, we describe a method to generate …

Megakaryocytes (MKs) are rare hematopoietic cells in the adult bone marrow and produce
platelets that are critical to vascular hemostasis and wound healing. Ex vivo generation of …

Human (h) induced pluripotent stem cells (iPSCs) are a potentially abundant source of blood
cells, but how best to select iPSC clones suitable for this purpose from among the many …

Induced pluripotent stem cell (iPSC) technology enables us to investigate various potential
iPSC-based therapies. Although the safety of iPSC derivation has not been completely …

The production of megakaryocytes (MKs)—the precursors of blood platelets—from human
pluripotent stem cells (hPSCs) offers exciting clinical opportunities for transfusion medicine …

In vitro cultured blood cells for transfusion purposes provide a safe alternative to donor
blood, particularly for patients who require recurrent transfusions, and can be used as …

De novo generation of haematopoietic stem cells from different human pluripotent stem cell
sources remains a high priority for haematology and regenerative medicine. At present …

In this paper, we describe a protocol for hematopoietic differentiation of human pluripotent
stem cells (hPSCs) and generation of mature myeloid cells from hPSCs through expansion …

Refractoriness to platelet transfusion is a major problem in a small group of patients, and
large-scale manufacturing of clinical grade functional platelets ex vivo has remained an …